In this study we show that CREBBP/EP300 HAT inhibition with the potent and selective inhibitor CPI-1612 can inhibit the growth of breast cancer cell lines in vitro and impede tumorigenesis in vivo at well tolerated doses with demonstrated target engagement. Here, TMPRSS11D is linked to breast carcinoma.